Abstract
The enzyme indoleamine 2,3-dioxygenase (IDO) regulates immune responses through the capacity to degrade the essential amino acid tryptophan into kynurenine and other downstream metabolites that suppress effector T-cell function and favour the differentiation of regulatory T cells. Considerable experimental evidence indicates that IDO can be expressed by dendritic cells, by tumour cells or by surrounding stromal cells, either within proximity of the tumour or at distal sites. Recent advances in the biochemistry of IDO and in our understanding of the biological relevance of IDOmediated tryptophan consumption to the establishment of dominant immune tolerance to cancer will be summarised and discussed. Within the wider context of cancer immunotherapy, this Review also delineates how IDO could be exploited as a molecular target for therapeutic intervention in order to boost anti-cancer immunity.
Keywords: Indoleamine 2,3-dioxygenase, immune tolerance, regulatory T cell, haematopoietic growth factors, cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Volume: 9 Issue: 2
Author(s): S. Rutella, G. Bonanno and R. De Cristofaro
Affiliation:
Keywords: Indoleamine 2,3-dioxygenase, immune tolerance, regulatory T cell, haematopoietic growth factors, cancer
Abstract: The enzyme indoleamine 2,3-dioxygenase (IDO) regulates immune responses through the capacity to degrade the essential amino acid tryptophan into kynurenine and other downstream metabolites that suppress effector T-cell function and favour the differentiation of regulatory T cells. Considerable experimental evidence indicates that IDO can be expressed by dendritic cells, by tumour cells or by surrounding stromal cells, either within proximity of the tumour or at distal sites. Recent advances in the biochemistry of IDO and in our understanding of the biological relevance of IDOmediated tryptophan consumption to the establishment of dominant immune tolerance to cancer will be summarised and discussed. Within the wider context of cancer immunotherapy, this Review also delineates how IDO could be exploited as a molecular target for therapeutic intervention in order to boost anti-cancer immunity.
Export Options
About this article
Cite this article as:
Rutella S., Bonanno G. and De Cristofaro R., Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187153009788452453
DOI https://dx.doi.org/10.2174/187153009788452453 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
H19: A Vital Long Noncoding RNA in the Treatment of Diabetes and Diabetic
Complications
Current Pharmaceutical Design Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued) Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Role of the Wnt/β-Catenin Pathway in the Pathogenesis of Alcoholic Liver Disease
Current Molecular Pharmacology Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Current Cancer Drug Targets Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets